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neurodegenerative and metabolic diseases, show tissue-
specific expression profiles and are associated with unique 
functional pathways. These results provide new insight into 
human diseases using unbiased genome-wide approaches.
Introduction
Mitochondrial dysfunction has been implicated in a broad 
range of human pathologies from neurodegenerative and 
cardiovascular diseases to inflammatory disorders, cancer, 
and aging (Ajith and Jayakumar 2014; Bonomini et al. 
2015; Coskun et al. 2012; Goncharov et al. 2015; Lane 
et al. 2015; Luo et al. 2015; Passos and Zglinicki 2012; 
Song et al. 2015; Wallace 2012). Mitochondrial function 
depends on proteins encoded by genes in both mitochon-
drial DNA (mtDNA) and the nuclear genome (composed of 
nuclear DNA, nDNA). The mitochondrial genome contains 
only 13 protein-coding genes, all of which are involved in 
electron transport chain (ETC) function and account for 
less than 1 % of the total mitochondrial proteome (mitopro-
teome), while nuclear genes encoding mitochondrial pro-
teins (mitonuclear genes) are responsible for the remain-
ing >99 % of mitochondrial proteins (Calvo et al. 2016; 
Pagliarini et al. 2008; Taanman 1999) (Fig. 1a). Rare muta-
tions in mitonuclear genes or mitochondrial DNA resulting 
in strong defects are known to cause human mitochondrial 
disorders, but the role of common genetic variation in mito-
nuclear genes in complex diseases is less straightforward. 
In particular, relationships between mitonuclear genes 
identified by genome-wide association studies (GWAS) and 
human diseases are often unclear. GWAS associations iden-
tify disease-associated variation and genetic loci of inter-
est but alone cannot reveal the directional impact of identi-
fied variation on gene product expression or function and 
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lack mechanistic or network setting. Accordingly, GWAS 
provide lists of candidate genes but determining biological 
context requires further study.
To better define the role of mitochondria in human 
disease we examined common genetic variation in mito-
nuclear genes in the context of human diseases using the 
National Human Genome Research Institute (NHGRI) 
genome-wide association study (GWAS) catalog. We found 
that major disease groups (cancer, cardiovascular disease, 
neurodegenerative disease, metabolic disease, inflamma-
tory disease, psychiatric disorders, and infectious disease) 
are associated with unique mitochondrial pathway signa-
tures, characterized by distinct protein–protein interaction 
networks based on STRING analysis as well as unique 
ontology sets. Genome-wide RNA sequencing expression 
data from 32 human tissues indicated unique tissue-specific 
expression profiles for each disease-associated mitonuclear 
gene group. Finally, examination of GWAS risk alleles 
using eQTL data revealed the directional impact of genetic 
perturbations on functional pathways, in addition to indi-
vidual genes, and provides a model for the contextual role 
of mitonuclear GWAS risk alleles in cancer. These unbi-
ased genome-wide assessments provide new insights into 
the pathway and tissue-specific roles of mitochondria in 
human diseases.
Results
A comprehensive mitonuclear GWAS catalog of human 
disease traits
To examine the role of common genetic variation in 
mitonuclear genes in human disease, we first compiled 
Fig. 1  Nuclear encoded mitochondrial proteins associated with 
human disease by GWAS. a The majority of mitochondrial proteins 
are encoded by the nuclear genome and genetic variation in both the 
nuclear or mitochondrial genome influences disease risk. b The mito-
chondrial proteome was cross-referenced against the entire human 
GWAS catalog and mitonuclear gene:disease associations were ana-
lyzed by disease type. c Mitonuclear genes are strongly enriched for 
GWAS disease associations compared to the whole protein-coding 
genome. d Overlapping genes between each of the disease groups 
and e statistical assessment of the similarity (overlap) of mitonuclear 
gene signatures between diseases by hypergeometric distribution 
(see “Methods”, see also Fig. S1). †p = 0.05, *p < 0.05, **p < 0.005, 
***p < 0.0005 (C cancer, ID inflammatory disease, ND neurodegen-
erative disease, MD metabolic disease, CVD cardiovascular disease)
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a comprehensive mitochondrial proteome using three 
resources: MitoCarta (Pagliarini et al. 2008), Integrated 
Mitochondrial Protein Index (IMPI) (Smith and Robinson 
2015), and the Gene Ontology (GO) Mitochondrion cata-
logue (Ashburner et al. 2000) (Fig. 1b). This combined list 
represents all 2349 genes encoding products demonstrated 
or predicted to localize to mitochondria (Supplemen-
tal File 1). Using the GWAS catalog (Welter et al. 2014) 
we extracted a total of 19,586 locus:trait associations at p 
value <1 × 10−5 that include disease traits, such as car-
diovascular disease and cancer, and non-disease traits, for 
example, hair color or political preferences. We curated this 
catalog to extract only disease-associated traits, resulting in 
8038 locus:disease associations.
We next cross-referenced this catalog against the mito-
chondrial proteome, using the nearest-neighbor SNP–gene 
assignments in the GWAS catalog, yielding 2055 mitonu-
clear locus:trait associations, including 888 mitonuclear 
locus:disease associations, arising from 583 unique mito-
nuclear genes (both trait lists provided in Supplemental 
File 2). Individual gene:disease associations were assigned 
to the following disease groups for further analysis: cancer, 
cardiovascular disease, neurodegenerative disease, meta-
bolic disease, inflammatory disease, psychiatric disorders, 
and infectious disease (Fig. 1b) (Supplemental File 2, Sup-
plemental File 3). Importantly, no mtDNA-encoded genes 
appear among these locus:trait associations, limiting all 
analyses to nuclear genes encoding mitochondrial proteins 
(mitonuclear genes.
Disease risk gene overlap
Pairwise comparisons of each disease group indicated sig-
nificant overlaps of associated genes between some dis-
ease pairs (Fig. 1d, e). In a recent study comparing similar 
disease groups using the whole genome, rather than just 
mitonuclear genes, we found cardiovascular and metabolic 
diseases share the most genes, while cancer and neurode-
generative disease show the least overlap (Johnson et al. 
2015). In contrast, among mitonuclear genes, cancer and 
neurodegenerative diseases show a high degree of over-
lap, while cardiovascular and metabolic diseases have only 
modest overlap (Fig. 1d, e; Fig. S1, see also Supplemental 
File 3). Significant overlap between disease pairs suggests 
common mitochondrial mechanisms underlying genetic 
risk associations.
Enrichment of protein–protein interactions 
in mitonuclear gene disease networks
Since gene products exert their functions through inter-
actions with other cellular components, the impact of a 
genetic perturbation can spread along the links of any 
functional network the gene product is involved in, disrupt-
ing network function (Barabasi et al. 2011). To investigate 
the network context of the mitonuclear gene sets associated 
with human disease, we analyzed each disease group using 
the Search Tool for the Retrieval of Interacting Genes/Pro-
teins (STRING) (Jensen et al. 2009), a database of known 
and predicted protein–protein interactions. We found each 
disease gene set to associate with unique protein–protein 
interaction network with varying degrees of interconnectiv-
ity and network interaction enrichment (Figs. 2, S2). The 
networks for cancer, inflammatory disease, neurodegenera-
tive disease, metabolic disease, and cardiovascular disease 
are significantly enriched for protein–protein interactions 
compared to the mitonuclear gene/GWAS background gene 
set, the most stringent approach (Fig. 2a–f, see “Methods”), 
while psychiatric disorders and infectious disease are not 
(Fig. S2a, b, Supplemental File 4). Notably, the degree of 
network interaction enrichment was not simply a result 
of the overall number of GWAS-identified genes in each 
group, i.e., cancer and psychiatric disorders had the same 
number of GWAS-identified genes but the cancer group 
was highly enriched for protein–protein interactions while 
psychiatric disorders group showed no interaction enrich-
ment (Figs. 2f, S2c).
Degree centrality of mitonuclear disease genes is 
associated with frequency in GWAS
The enrichment of unique protein–protein interaction net-
works among the major disease groups is consistent with a 
model where complex diseases are driven by the impact of 
gene products on functional networks. This model suggests 
that gene products centrally involved in key functional 
networks might have stronger phenotypic effects, through 
their many network interactions, and would consequently 
be associated with stronger genetic associations and appear 
more frequently in GWAS. Indeed, genes with the high-
est number of GWAS instances in cancer, inflammatory 
disease, and neurodegenerative disease also tend to be the 
most highly interconnected within their respective networks 
(Fig. 2). To examine the correlation between GWAS hot-
spots and network connectedness, we analyzed the number 
of network interactions (degree centrality) of mitonuclear 
genes appearing only once in the GWAS catalog for a given 
disease group, compared to those appearing multiple times 
(Figs. 2g, S2d). As a network-based assessment would pre-
dict, genes appearing more than once in the GWAS catalog 
do have more network interactions than those appearing 
only once. Cardiovascular disease, inflammatory disease, 
and the complete mitonuclear gene set show a statistically 
significantly enrichment for network interactions among 
genes appearing more than once in the GWAS catalog 
compared to those with only one GWAS occurrence. Other 
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networks show only modest trend, although these analyses 
are undoubtedly limited in statistical power by the size of 
the datasets available.
Mitochondrial pathways of disease
We next searched for the enriched Gene Ontology (GO) 
terms for each disease group using the mitonuclear gene 
GWAS set as background (the most stringent approach). 
We found that the cardiovascular disease set is significantly 
enriched (p < 0.05 after FDR multiple testing correction) 
for five terms (Table 1): lipoprotein particle binding, sterol 
binding, cholesterol binding, lipoprotein particle receptor 
binding, and alcohol binding. Inflammatory disease set 
is significantly enriched in 44 terms, which primarily 
associated with wound healing, stress response, immune 
responses, and cellular proliferation. Metabolic disease is 
significantly enriched for β-amyloid binding, cellular com-
ponent biogenesis, and response to stimulus. No term from 
the neurodegenerative disease group achieved FDR-cor-
rected significance, but those reaching nominal significance 
p < 0.05 include lipoprotein binding, tau binding, and terms 
associated with myelin, intracellular trafficking, and cal-
cium (see also Supplemental File 4).
The cancer gene set was the most striking in 
both the STRING network and GO analyses. In 
Fig. 2  Mitonuclear gene groups associated with disease in GWAS 
are significantly enriched for protein–protein interactions. STRING 
networks generated from the gene products of mitonuclear genes 
associated with a cancer, b inflammatory disease, c neurodegen-
erative disease, d metabolic disease, and e cardiovascular disease. 
Number of disease-specific GWAS catalog appearances indicated 
by the shade of the network symbol. Isolated gene products with no 
network interactions omitted from these plots. f Total genes in each 
disease group, percentage present in each interaction network, and 
p values for enrichment of protein–protein interactions by STRING 
pathway analysis. Infectious disease and psychological disorders 
were not enriched for protein–protein interactions (see Fig. S2). g 
Number of network interactions for each mitonuclear gene appear-
ing once or more than once in the GWAS catalog by disease group; 
***p < 0.0005, ****p < 0.0001, †p = 0.15 by pairwise t test. (see 
Supplemental File 4) (C cancer, ID inflammatory disease, ND neu-
rodegenerative disease, MD metabolic disease, CVD cardiovascular 
disease)
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Table 1  Gene ontology terms enriched in disease-associated mitonuclear gene sets
GO Term p value FDR p value
Cancer
 BP Intrinsic apoptotic signaling pathway 2.26E−07 2.97E−03
 BP Response to external biotic stimulus 7.33E−07 2.97E−03
 BP Response to other organism 7.33E−07 2.97E−03
 BP Response to biotic stimulus 8.83E−07 2.97E−03
 BP Cell type-specific apoptotic process 1.27E−06 3.41E−03
 BP Intrinsic apoptotic signaling pathway in response to DNA damage 2.34E−06 5.24E−03
 BP Positive regulation of mito. outer mem. perm. involved in apoptotic signaling 3.98E−06 7.64E−03
 BP Response to virus 8.46E−06 1.42E−02
 BP Regulation of mito. outer mem. perm. involved in apoptotic signaling 1.50E−05 2.18E−02
 BP Digestive system development 1.95E−05 2.18E−02
 BP Positive regulation of protein insertion into mito. mem. in apoptotic signaling 1.95E−05 2.18E−02
 BP Regulation of proteasomal ubiquitin-dependent protein catabolic process 2.10E−05 2.18E−02
 BP Anatomical structure formation involved in morphogenesis 3.71E−05 3.56E−02
Metabolic disease
 MF Beta-amyloid binding 6.56E−06 2.58E−02
 BP Positive regulation of cellular component biogenesis 3.57E−06 3.11E−02
 BP Response to light stimulus 4.63E−06 3.11E−02
Cardiovascular disease
 MF Lipoprotein particle binding 6.56E−06 1.29E−02
 MF Sterol binding 1.37E−05 1.35E−02
 MF Cholesterol binding 1.37E−05 1.35E−02
 MF Lipoprotein particle receptor binding 2.59E−05 2.04E−02
 MF Alcohol binding 7.37E−05 4.83E−02
Inflammatory disease*
 BP Intracellular signal transduction 6.51E−08 8.75E−04
 BP Response to stress 4.68E−07 3.15E−03
 BP Wound healing 7.25E−07 3.19E−03
 BP Defense response 9.49E−07 3.19E−03
 BP Response to wounding 2.02E−06 5.44E−03
 BP Regulation of body fluid levels 4.58E−06 8.09E−03
 BP Regulation of intracellular signal transduction 5.62E−06 8.09E−03
 BP Regulation of multicellular organismal process 5.71E−06 8.09E−03
 BP Blood coagulation 6.59E−06 8.09E−03
 BP Coagulation 6.59E−06 8.09E−03
 BP Regulation of defense response 7.38E−06 8.09E−03
 BP Positive regulation of multicellular organismal process 7.66E−06 8.09E−03
 BP Hemostasis 7.93E−06 8.09E−03
 BP Regulation of protein metabolic process 8.42E−06 8.09E−03
 BP Regulation of primary metabolic process 1.46E−05 1.31E−02
Neurodegenerative disease†
 MF Tau protein binding 3.37E−05 ns
 MF Structural constituent of myelin sheath 1.06E−03 ns
 MF Phospholipase binding 1.06E−03 ns
 MF Lipoprotein particle binding 3.11E−03 ns
 MF Kinesin binding 6.08E−03 ns
 MF Ankyrin binding 9.92E−03 ns
 MF Calcium ion binding 3.90E−02 ns
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cancer, protein–protein interactions are highly enriched: 84 
observed compared to 34 expected, with an enrichment p 
value of 6.58 × 10−11. A cluster of highly interconnected 
factors is readily apparent, composed of well-known tumor 
suppressors and proto-oncogenes involved in apoptosis 
including BCL-2, BAK, TERT, and CASP8 (Hassan et al. 
2014; Shortt and Johnstone 2012) (Fig. 2a). In addition to 
the cluster of apoptosis-regulating genes in the STRING 
network, GO analysis of the cancer mitonuclear gene set 
revealed significant enrichment of terms related to the regu-
lation of apoptosis (Table 1). Importantly, intrinsic apopto-
sis, involving mitochondrial outer membrane permeabili-
zation as a mediator of cell death signaling, is specifically 
enriched, and the most significant GO term is ‘intrinsic 
apoptotic signaling pathway’.
Tissue‑specific expression of disease‑associated 
mitonuclear gene sets
Mitochondria perform a wide range of functions that are of 
differential importance in different tissues, and tissue-spe-
cific roles of mitochondria undoubtedly contribute to the 
role of this organelle in disease. To explore tissue specific-
ity of the expression of genes within each group, we used 
recently published RNA-seq data studying genome-wide 
gene expression in 32 different tissues (Uhlen et al. 2015), 
comparing the relative expression of genes in each group 
with both the whole proteome and the mitonuclear pro-
teome (Fig. 3; Supplemental File 5, see “Methods”). We 
found that each disease gene set is associated with a unique 
tissue expression profile. Strikingly, the neurodegenerative 
disease gene set is specifically highly expressed in cer-
ebral cortex, while the genes in the metabolic disease group 
show high expression in liver, intestines, and duodenum. 
In these diseases, the GWAS-identified genes appear to be 
specifically highly expressed in disease target tissues. By 
contrast, cancer, cardiovascular disease, and psychiatric 
disorders show similar expression throughout all 32 tissues. 
Thus, in some diseases expression of the disease-associated 
genes is enriched in known target tissues, while genes asso-
ciated with other diseases, such as cancer, show no tissue 
overt specificity.
Cancer mitonuclear GWAS provides novel insights 
into pathways of cancer risk
Given the striking enrichment of the intrinsic apoptotic 
pathway in the cancer network, we decided to examine this 
group in greater depth. The STRING network for cancer 
can be divided into three sub-network clusters: a cluster 
ns not significant
* Truncated at 15 most significant terms
† Nominally significant terms
Table 1  continued
GO Term p value FDR p value
 MF Calcium-dependent protein binding 4.02E−02 ns
 MF Copper ion binding 4.81E−02 ns
Fig. 3  Mitonuclear disease gene sets have unique tissue expression 
patterns. a Relative median expression of each mitonuclear disease 
gene group by tissue type compared to the whole proteome and the 
mitonuclear proteome (see “Methods”, Supplemental File 5). Pair-
wise statistical significance (Wilcoxon rank-sum test) of difference 
between each disease group and the whole proteome or mitonuclear 
proteome is indicated by color of dot in the upper and lower right-
hand corners, respectively. b Example box-and-whisker plot of mito-
nuclear gene expression in cerebral cortex by disease gene group. 
*p < 0.05. **p < 0.005 by Wilcoxon rank-sum test
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of apoptosis genes, a cytoskeleton/signaling cluster, and 
a metabolic cluster (Fig. 4a red, blue, and green regions, 
respectively). To investigate whether the GWAS-identified 
SNPs are associated with altered gene expression, which 
might functionally impact the integrity of these sub-net-
works, we examined the variants by gene-level cis expres-
sion quantitative trait loci (eQTLs) analysis and determined 
the directional effect of risk alleles using the Genotype-
Tissue Expression (GTEx) database (http://www.gtexpor-
tal.org) (Carithers and Moore 2015) (see “Methods”). We 
divided the genes involved in the ‘apoptosis’ cluster into 
‘tumor suppressors’ and ‘tumor promoters’ based on their 
known pro- or anti-apoptotic effects, respectively. Strik-
ingly, eQTL analysis reveals that GWAS risk alleles in 
‘tumor promoters’ are associated with increased expression 
while ‘tumor suppressors’ are associated with decreased 
expression or no change (Fig. 4a–c). While only three 
BAK1 SNPs and the pooled medians for pro-apoptotic 
genes reach statistical significance, the directionalities of 
the remaining gene–SNP pairs are consistent with reduced 
pro-apoptotic signaling (see also Supplemental File 6).
Among genes in the cytoskeleton cluster, two cis-eQTLs 
were significant: PDLIM5 (PDZ And LIM Domain protein 
5) and STK35 (serine–threonine kinase Clik1, also known 
as PDLIM interacting kinase 1), with the cancer risk alleles 
associating with significantly decreased and increased 
expression, respectively (Fig. 4d). STK35/Clik1 regulates 
gene expression, while the PDZ-LIM family comprises 
stress fiber-associated proteins that control regulatory fac-
tors through sequestration in the cytoplasm; at least one 
PDLIM family member has been shown to directly tar-
get STK35 to stress fibers (Vallenius and Makela 2002). 
The other gene products in the cytoskeletal cluster, CFL1 
(cofilin 1), ACTN1 (alpha actinin 1), and ERBB4 (encod-
ing receptor tyrosine protein kinase erbB-4), all interact 
to regulate actin stress fibers (Hirata et al. 2015; Opitz 
et al. 2015). Moreover, the STK35 homologue STK35L1 
is a known regulator of the tumor suppressor p16(INK4a) 
(Goyal et al. 2011). Thus, the directional effects of the risk 
alleles on expression of STK35 or PDLIM5 are consistent 
with increased cancer risk (Fig. 4e).
Discussion
Using unbiased assessment of GWAS, RNA sequencing, 
and eQTL datasets, we have identified unique disease-spe-
cific protein interaction networks, functional pathways, and 
tissue-specific expression patterns of mitonuclear genes 
(Fig. 5). In cancer, GWAS risk genes are primarily enriched 
for one process, intrinsic apoptosis, and are broadly and 
systemically expressed. Similarly, cardiovascular disease 
Fig. 4  Mitonuclear cancer associations and eQTL data reveal direc-
tional impact of risk alleles on intrinsic apoptosis and intracellular 
signaling. a The cancer mitonuclear GWAS network includes three 
overlapping sub-networks: intrinsic apoptosis, cytoskeleton/signaling, 
and metabolic. Among the intrinsic apoptosis factors, tumor promot-
ers and tumor suppressors are indicated in red and blue, respectively. 
b, c eQTL data for tumor suppressors and oncogenes, respectively. 
Direction of eQTL effect is overlaid on a using arrows. d eQTL 
data for cytoskeletal/signaling genes in the cancer network (direc-
tion and significance overlaid in a). e A putative model for the rela-
tionship between the cytoskeletal/signaling network and cancer risk. 
*p < 0.05, **p < 0.005 by one-sample t test (see Supplemental Data)
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is enriched for one pathway, lipoprotein metabolism, with 
no apparent tissue-specific expression. Inflammatory dis-
ease is enriched for intracellular signaling genes, especially 
in response to stress, highly expressed in multiple tissues 
including lymph nodes, spleen, tonsil, and appendix. Meta-
bolic disease and neurodegenerative disease genes are both 
enriched for lipoprotein/amyloid processes but show dif-
ferential tissue expression: metabolic disease-associated 
genes are highly expressed in liver and intestines while 
neurodegenerative disease genes are highly and specifi-
cally expressed in the brain. As a whole, these data indicate 
that while mitochondrial dysfunction is ubiquitously linked 
to a wide range of pathologies in humans, the landscape 
of common genetic variation among mitonuclear genes is 
highly disease specific, as are the mechanistic relationships 
between mitochondria and disease both in regard to mito-
chondrial pathways and tissue-specific expression.
The striking differences in tissue expression between 
cancer, where there are no apparent tissue-specific expres-
sion profiles, and diseases such as neurodegenerative dis-
ease, which shows a highly tissue-specific expression 
pattern, are particularly interesting. With only tissue expres-
sion data these differences would be difficult to reconcile, 
but the pathway- and function-based analyses provide some 
clues. From these data, it appears that the mitochondrial 
pathways involved in cancer are highly evolutionarily con-
served pathways likely to function in most or all human 
cell types, whereas the pathways of neurodegenerative dis-
ease, which include amyloid processing and lipoprotein 
metabolism, are more recently evolved and likely enact tis-
sue-specific functions. Perhaps more interesting are the dif-
ferences in expression profiles between neurodegenerative 
disease and metabolic disease, which show enrichment of 
overlapping pathways but unique tissue expression profiles 
among disease-associated genes. This indicates that genetic 
perturbations of genes involved in lipoprotein metabolism 
processes can lead to either neurodegenerative disease or 
metabolic disease, depending on where the perturbed fac-
tor is expressed (see Fig. 5). Together, these results provide 
some insight into the pathogenesis of complex genetic dis-
eases and suggest that tissue targeting should be considered 
when developing therapeutic strategies.
The challenge of exploiting the ever-expanding GWAS 
catalog is to find functional insight into disease processes in 
seemingly disparate sets of genes. Here, we used network-
based approaches to study the GWAS mitonuclear genes in 
bulk. Our results provide new insight into the relationship 
between mitochondria and human disease and open new 
avenues for research. The cancer intrinsic apoptosis eQTL 
findings demonstrate that the directional impact of risk 
variants on gene expression can predict target pathways for 
intervention. Pharmaceutical agents targeting the intrinsic 
apoptotic pathway are already in experimental and clinical 
use (Almstedt and Schmidt 2015; Mohana-Kumaran et al. 
Fig. 5  The role of common genetic variation in mitonuclear genes in 
human disease. Network and pathway analysis of mitonuclear GWAS 
and genome-wide expression data reveals unique pathways and tis-
sue expression patterns underlying mitonuclear gene–disease associa-
tions. Mitonuclear cancer-associated genes are enriched for intrinsic 
apoptosis and broadly expressed. Cardiovascular disease mitonuclear 
genes are enriched for lipoprotein metabolism with no tissue show-
ing significantly higher expression than the background. Inflamma-
tory disease is enriched for signaling genes, with high expression 
in lymph, spleen, tonsil, appendix, and other tissues. Metabolic and 
neurodegenerative mitonuclear genes are enriched for lipoprotein/
amyloid processes but show differential tissue expression: metabolic 
disease genes are highly expressed in liver and intestines while neuro-
degenerative disease genes are highly expressed in brain
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2014; Mukherjee et al. 2015; Opitz et al. 2015; Paraiso 
et al. 2012; Subramaniam et al. 2015; Yaswen et al. 2015), 
so it is readily conceivable that cancer patients could be 
screened for variants in this hub and treatment designed 
based on their genotype. In addition, our findings of tissue 
specificity in certain disease gene sets reinforces the impor-
tance of considering tissue specificity in drug screening and 
development, while also suggesting that interventions tar-
geted to the tissue of interest may provide greater benefit 
with fewer off-target effects.
This study utilized both genetic association studies and 
experimental expression data but is limited by a lack of 
functional studies characterizing the impact of GWAS risk 
alleles on cellular and molecular endpoints beyond gene 
expression. Such studies will provide critical links between 
large-scale human genetic findings and disease pathogen-
esis, solidly tying these in silico findings to human biology. 
An additional caveat in our findings is that while our study 
was aimed at characterizing the role of genetic variation in 
mitonuclear genes in human disease, and most of the sig-
nificant findings are indeed bona fide mitochondrial path-
ways, many specific genes and identified do not have obvi-
ous direct mitochondrial roles. The composite mitonuclear 
gene list was intended to be comprehensive and contains 
any genes whose products have been reported to localize 
to mitochondria. Thus, while the findings reported here 
are comprehensive, specific factors may be only loosely 
relevant to mitochondrial biology. While generation of a 
comprehensive and accurate mitochondrial proteome is an 
active area of research and our study is limited by available 
data, we cross compared the protein interaction networks in 
Fig. 2 with the cellular localization database COMPART-
MENTS (see “Methods”) to provide additional context for 
our findings (Binder et al. 2014). The COMPARTMENTS 
database assesses the strength of evidence showing locali-
zation of proteins to cellular compartments, including mito-
chondria, by distilling multiple localization resources into 
a simple score, where higher scores (maximum 5) indicate 
stronger evidence for mitochondrial localization. This com-
parison revealed that highly connected factors in the net-
work maps tend to show strong experimental evidence sup-
porting mitochondrial localization, suggesting that even if 
a more stringent localization cutoff were available the key 
findings would be unchanged (Fig. S3).
Finally, it is important to emphasize that only the mito-
nuclear genome was examined, as no mtDNA-encoded 
genes appear among GWAS catalog disease trait associa-
tions. Properties of the mitochondrial genome such as copy 
number variance and heteroplasmy, the presence of multi-
ple forms of mtDNA in the same cell or organism, neces-
sitate distinct methodologies. Although encoding less than 
one percent of mitochondrial proteins, the proteins encoded 
are key to core mitochondrial function, and the impact of 
genetic variation in the mitochondrial genome warrants fur-
ther study.
Methods
Mitochondrial proteome and mitonuclear GWAS 
compilation
Datasets to compile the genes encoding the mitochondrial 
proteome were downloaded during July, 2015, from Mito-
Carta (downloaded from http://www.broadinstitute.org/
node/7098/index.html) (Pagliarini et al. 2008), the Inte-
grated Mitochondrial Protein Index (IMPI) (downloaded 
from http://www.mrc-mbu.cam.ac.uk/impi) (Smith and 
Robinson 2015), and the Gene Ontology (GO) Mitochon-
drion catalogue (downloaded from MitoMiner at http://
mitominer.mrc-mbu.cam.ac.uk) (Ashburner et al. 2000; 
Smith et al. 2012; Smith and Robinson 2015). The NHGRI 
GWAS catalog was downloaded in July 2015, and is avail-
able at https://www.ebi.ac.uk/gwas/ (Welter et al. 2014).
During submission of this manuscript an updated Mito-
Carta, MitoCarta 2.0, was published (Calvo et al. 2016). 
While the new MitoCarta contains approximately 20 % 
more proteins that the original, most of these factors were 
already present in our comprehensive mitochondrial pro-
teome lists. MitoCarta 2.0 would add only 26 genes to our 
total gene set, only 15 of which are associated with disease 
traits by GWAS, additions that would not have substantially 
impacted our results. These are provided in Supplementary 
File 7.
Statistical assessments
Statistical significance of GWAS association enrichment 
among mitonuclear genes was calculated by Chi-square 
test using GraphPad Prism. Overlap of genes within each 
disease group was statistically assessed by hypergeo-
metric distribution using the R script dyper, part of the R 
Stats package (https://stat.ethz.ch/R-manual/R-patched/
library/stats/html/Hypergeometric.html). Enrichments of 
protein–protein interactions and GO terms among disease-
associated gene sets were calculated using the web-based 
interface for the STRING network database (http://string-
db.org/). All enrichments were calculated using the gene 
list in the mitonuclear gene GWAS disease set as the back-
ground gene list, the most stringent method, unless stated 
otherwise.
STRING networks
Protein–protein interaction networks were generated and 
assessed using the web-based Search Tool for the Retrieval 
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of Interacting Genes/Proteins (STRING) pathway analysis 
tool (http://string-db.org/) (Szklarczyk et al. 2015). Net-
works presented in figures are curated to omit targets with 
no interactions (isolated from the network) and to overlay 
the number of GWAS catalog appearances for each gene in 
each disease group.
Assessment of tissue‑specific gene expression
Tissue-specific expression was examined using the recently 
published genome-wide RNA sequencing data from 32 
human tissues (Uhlen et al. 2015). Pairwise comparisons 
between each group of genes and either the whole-tran-
scriptome background or the mitonuclear gene set tran-
script background were performed using the Wilcox rank-
sum test. Box plots represent Log2 Fragments per Kilobase 
of exon Per Million fragments Mapped (FPKM) +0.25. 
Bold bars represent median values, while the box spans 
the first to third quintile. Whiskers show minimum and 
maximum values with outliers, defined as ≥3 interquartile 
ranges above the third or below the first quartile, excluded.
Assessment of GWAS variant eQTL directionality 
and significance
eQTL data in Fig. 4 were extracted from the GTEx Portal 
database (http://www.gtexportal.org/home/). Data in scatter 
plots represent eQTL data from all available tissues with 
directionality relative to GWAS risk allele. Data were ana-
lyzed and plotted using GraphPad Prism, with bars indicat-
ing interquartile range and statistical significance assessed 
using the two-tailed, one-sample t test method.
R scripts and gene expression files
Script, text file descriptions, and gene expression files have 
been uploaded to the repository GitHub under the follow-
ing URL: https://github.com/qwzhang0601/Network_anal-
ysis_of_mitonuclear_GWAS_gene_expression_in_tissues.
Assessment of mitochondrial localization using 
compartments
To cross-examine evidence for mitochondrial localization 
of the factors involved the protein–protein interaction net-
works in Fig. 2, we queried the cell compartment locali-
zation database COMPARTMENTS (Binder et al. 2014) 
using the available web-based tool (http://compartments.
jensenlab.org/Search). Values for each factor in Fig. 2 are 
indicated in Figure S3. For our purposes, scores of 0 and 
1 were combined to a score of 1 as each factor in these 
networks appeared in at least one mitochondrial proteome 
dataset to appear in our analyses.
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